Valvular & structural heart diseaseTrial design
Effect of anti-fibrotic therapy on regression of myocardial fibrosis after transcatheter aortic valve implantation (TAVI): design and rationale of the Reduce-MFA DZHK25 trial
- national, prospective, randomized, parallel group, controlled, open-label interventional multi-centre trial with blinded outcome assessment (PROBE design)
- design and rationale
Study context
- Population
- Patients with severe aortic stenosis (AS) scheduled for TAVI with high baseline fibrotic burden (cardiac MRI (CMR)-derived ECV% ≥ 25.9%)enrolled, 153 randomized · enrolled 384 · randomized 153
- Participants
- 384 patients
- Planned comparison
- anti-fibrotic therapy vs Standard of Care alone
No results yet. This paper sets out the design of a trial; its results are to come.
Further findings
Recruitment
- enrolled
- 384
- randomized
- 153
- recruitment recently completed
Original publication
Effect of anti-fibrotic therapy on regression of myocardial fibrosis after TAVI: design and rationale of the Reduce-MFA DZHK25 trial. ESC Heart Fail. Published 12 May 2026. doi:10.1093/eschf/xvag083
Summarised from the published abstract; every number is checked against it